Philippe Girard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Philippe Girard has a total of 370 co-authors. Here are the top co-authors by number of shared publications:
- Laurent Bertoletti
Université Jean Monnet Saint-Étienne, CHU Saint-Étienne, Mines Saint-Etienne, INSERM, SAINBIOSE U1059, CIC 1408, Département of Médecine Vasculaire et Thérapeutique, F-CRIN INNOVTE network, Saint-Etienne, France
11 shared publications - Isabelle Mahé
Assistance Publique - Hopitaux de Paris, Île-de-France, France
10 shared publications - Francis Couturaud
INSERM UMR 1304‐GETBO, Univ Brest Brest France
9 shared publications - Olivier Sanchez
Paris Cité University, Paris, France
9 shared publications - Antoine Elias
Cardiology and Vascular Medicine, Sainte Musse Hospital, Toulon Hospital Centre, Toulon, France
8 shared publications Guy Meyer
Service de Pneumologie et Soins Intensifs, Hôpital Européen Georges Pompidou, APHP, Université de Paris, Paris, France; INSERM UMR_S1140, Innovations Thérapeutiques en Hémostase, Laboratoire de Chirurgie expérimentale, Fondation Alain Carpentier, Paris, France; F-CRIN INNOVTE Network, Saint-Etienne, France
8 shared publications
Latest Publications
- Open Access
- 26 June 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 12 (6) , 447-457
API-CAT Investigators’ Decisions on Anticoagulation following Extended Treatment for Cancer VTE
Background: The API-CAT trial demonstrated that reduced-dose apixaban (2.5 mg twice daily) was noninferior to full-dose apixaban (5 mg twice daily) for the prevention of recurrent venous thromboembolism in patients with cancer, while resulting in fewer clinically relevant bleeding events. Although these findings are expected to influence clinical practice, real-world data on physicians’ anticoagulation decisions in this setting remain limited. Objectives: To describe investigators’ anticoagulant treatment decisions for patients enrolled in the API-CAT trial after discontinuation of blinded study treatment and prior to trial unblinding and dissemination of results. Methods: This descriptive analysis included patients from the prospective, multicenter, randomized, double-blind API-CAT trial who received at least one dose of study medication. Investigators prospectively documented anticoagulation management following either premature or planned discontinuation of blinded apixaban. Decisions were categorized as treatment discontinuation, continuation at a reduced dose, or continuation at a full dose. Descriptive analyses examined treatment choices according to patient characteristics, cancer features, and contextual factors. Results: Of 1,766 randomized patients, 1,458 (82.6%) were included in the analysis. After discontinuation of study treatment, anticoagulation was stopped in 198 patients (13.6%) and continued in 1,260 (86.4%). Among those continuing therapy, 790 patients (62.7%) received full-dose anticoagulation, 465 (36.9%) received a reduced dose, 5 unknown. Direct oral anticoagulants (DOACs) were prescribed in 89.6% of cases, and low-molecular-weight heparin in 9.9%. Treatment decisions were generally consistent across patient and cancer characteristics but varied according to timing of treatment discontinuation, physician specialty, and country. Conclusions: Prior to unblinding of the API-CAT trial, treatment decisions appeared poorly driven by clinical characteristics, reflecting a “therapeutic grey zone” where anticoagulation was continued in most patients but with highly variable dosing. This exploratory snapshot provides a baseline to monitor the anticipated shift toward wider adoption of reduced-dose apixaban for extended anticoagulation following publication of the API-CAT results. The substantial proportion of treatment discontinuation highlights the need for further studies to identify patients who may safely stop therapy.
- 26 June 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 12 (6) , 447-457
Open AccessAPI-CAT Investigators’ Decisions on Anticoagulation following Extended Treatment for Cancer VTE
Background: The API-CAT trial demonstrated that reduced-dose apixaban (2.5 mg twice daily) was noninferior to full-dose apixaban (5 mg twice daily) for the prevention of recurrent venous thromboembolism in patients with cancer, while resulting in fewer clinically relevant bleeding events. Although these findings are expected to influence clinical practice, real-world data on physicians’ anticoagulation decisions in this setting remain limited. Objectives: To describe investigators’ anticoagulant treatment decisions for patients enrolled in the API-CAT trial after discontinuation of blinded study treatment and prior to trial unblinding and dissemination of results. Methods: This descriptive analysis included patients from the prospective, multicenter, randomized, double-blind API-CAT trial who received at least one dose of study medication. Investigators prospectively documented anticoagulation management following either premature or planned discontinuation of blinded apixaban. Decisions were categorized as treatment discontinuation, continuation at a reduced dose, or continuation at a full dose. Descriptive analyses examined treatment choices according to patient characteristics, cancer features, and contextual factors. Results: Of 1,766 randomized patients, 1,458 (82.6%) were included in the analysis. After discontinuation of study treatment, anticoagulation was stopped in 198 patients (13.6%) and continued in 1,260 (86.4%). Among those continuing therapy, 790 patients (62.7%) received full-dose anticoagulation, 465 (36.9%) received a reduced dose, 5 unknown. Direct oral anticoagulants (DOACs) were prescribed in 89.6% of cases, and low-molecular-weight heparin in 9.9%. Treatment decisions were generally consistent across patient and cancer characteristics but varied according to timing of treatment discontinuation, physician specialty, and country. Conclusions: Prior to unblinding of the API-CAT trial, treatment decisions appeared poorly driven by clinical characteristics, reflecting a “therapeutic grey zone” where anticoagulation was continued in most patients but with highly variable dosing. This exploratory snapshot provides a baseline to monitor the anticipated shift toward wider adoption of reduced-dose apixaban for extended anticoagulation following publication of the API-CAT results. The substantial proportion of treatment discontinuation highlights the need for further studies to identify patients who may safely stop therapy.
- Open Access
- 28 August 2025
- Published by Elsevier in Archives of Cardiovascular Diseases
- Vol. 118 (12) , 687-696
The management of cancer-associated thromboembolism: Proposals from the French multidisciplinary INNOVTE CAT Working Group
- 28 August 2025
- Published by Elsevier in Archives of Cardiovascular Diseases
- Vol. 118 (12) , 687-696
Open AccessThe management of cancer-associated thromboembolism: Proposals from the French multidisciplinary INNOVTE CAT Working Group
- 3 August 2024
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 45 (8) , 498-511
Traduction et republication de : « Événements thromboemboliques artériels liés au cancer »
- 3 August 2024
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 45 (8) , 498-511
Traduction et republication de : « Événements thromboemboliques artériels liés au cancer »
- Open Access
- 25 June 2024
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 43, 100990
Suspected pulmonary embolism in the emergency department: over-, under- and/or mis-testing?
- 25 June 2024
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 43, 100990
Open AccessSuspected pulmonary embolism in the emergency department: over-, under- and/or mis-testing?
- 21 June 2024
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 45 (7) , 437-443
Traduction et republication de : « Traitement de la maladie thromboembolique veineuse associée au cancer chez les patients en soins palliatifs »
- 21 June 2024
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 45 (7) , 437-443
Traduction et republication de : « Traitement de la maladie thromboembolique veineuse associée au cancer chez les patients en soins palliatifs »
- 27 May 2024
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 45 (5) , 289-299
Traduction et republication de : « Maladie thromboembolique veineuse récidivante chez les patients cancéreux anticoagulés : diagnostic et traitement »
- 27 May 2024
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 45 (5) , 289-299
Traduction et republication de : « Maladie thromboembolique veineuse récidivante chez les patients cancéreux anticoagulés : diagnostic et traitement »
- 23 May 2024
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 45 (6) , 366-381
Traduction et republication de : « Prise en charge de la maladie thromboembolique veineuse associée au cancer chez les populations vulnérables »
- 23 May 2024
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 45 (6) , 366-381
Traduction et republication de : « Prise en charge de la maladie thromboembolique veineuse associée au cancer chez les populations vulnérables »
- 23 November 2023
- Published by Elsevier in Archives of Cardiovascular Diseases
- Vol. 117 (1) , 84-93
Recurrent venous thromboembolism in anticoagulated cancer patients: Diagnosis and treatment
- 23 November 2023
- Published by Elsevier in Archives of Cardiovascular Diseases
- Vol. 117 (1) , 84-93
Recurrent venous thromboembolism in anticoagulated cancer patients: Diagnosis and treatment
- 23 November 2023
- Published by Elsevier in Archives of Cardiovascular Diseases
- Vol. 117 (1) , 72-83
Central venous catheter associated upper extremity deep vein thrombosis in cancer patients: Diagnosis and therapeutic management
- 23 November 2023
- Published by Elsevier in Archives of Cardiovascular Diseases
- Vol. 117 (1) , 72-83
Central venous catheter associated upper extremity deep vein thrombosis in cancer patients: Diagnosis and therapeutic management